Investing in Transformative Biotech Companies

The Aescap funds invest in publicly traded biotech / life sciences companies. They invest in high-growth, innovative companies that develop and market new medicines and in some cases diagnostics and medical devices. The funds comply with the Dutch Authority Financial Markets (AFM) and are managed by a broad and experienced team with a great track record. A team that has invested a significant amount of money in the Aescap funds themselves. Aescap aims to generate preferred financial returns by choosing a focused investment approach picking around 20 companies per fund. It acts as a private equity player on the stock market by being heavily involved in the companies it invests in. The name Aescap is derived from ‘Aesculapius’, the Roman god of Medicine, and ‘Capital’.


The companies in the portfolios of the Aescap biotech funds address medical needs that are not met by products available today.

We believe everybody has the right to receive the best medical care available. Aescap’s investments have positively affected society and have already resulted in an improvement of the quality of life of millions of people worldwide.

Update via Webcast

Our presentation for existing and interested investors is currently replaced by a webcast. The next webcast will be held on March 16, 2023 at 15:00 CET.

Meet the Investment Team

The Aescap investment team, led by portfolio manager Patrick Krol, consists of experienced professionals with different backgrounds in the health care industry. Aescap aims to providing a good financial return to their investors, and in parallel contribute to improving the well-being of millions of people. The team invests in the Aescap funds themselves with over 25 million euro.

Subscribe to our Newsletter here.

    Latest news

    Biotech Enters New Phase

    Biotech companies are rapidly developing new technologies to treat previously incurable diseases.